Literature DB >> 16648484

Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.

Gang G Wang1, Martina P Pasillas, Mark P Kamps.   

Abstract

Homeobox transcription factors Meis1 and Hoxa9 promote hematopoietic progenitor self-renewal and cooperate to cause acute myeloid leukemia (AML). While Hoxa9 alone blocks the differentiation of nonleukemogenic myeloid cell-committed progenitors, coexpression with Meis1 is required for the production of AML-initiating progenitors, which also transcribe a group of hematopoietic stem cell genes, including Cd34 and Flt3 (defined as Meis1-related leukemic signature genes). Here, we use dominant trans-activating (Vp16 fusion) or trans-repressing (engrailed fusion) forms of Meis1 to define its biochemical functions that contribute to leukemogenesis. Surprisingly, Vp16-Meis1 (but not engrailed-Meis1) functioned as an autonomous oncoprotein that mimicked combined activities of Meis1 plus Hoxa9, immortalizing early progenitors, inducing low-level expression of Meis1-related signature genes, and causing leukemia without coexpression of exogenous or endogenous Hox genes. Vp16-Meis1-mediated transformation required the Meis1 function of binding to Pbx and DNA but not its C-terminal domain (CTD). The absence of endogenous Hox gene expression in Vp16-Meis1-immortalized progenitors allowed us to investigate how Hox alters gene expression and cell biology in early hematopoietic progenitors. Strikingly, expression of Hoxa9 or Hoxa7 stimulated both leukemic aggressiveness and transcription of Meis1-related signature genes in Vp16-Meis1 progenitors. Interestingly, while the Hoxa9 N-terminal domain (NTD) is essential for cooperative transformation with wild-type Meis1, it was dispensable in Vp16-Meis1 progenitors. The fact that a dominant transactivation domain fused to Meis1 replaces the essential functions of both the Meis1 CTD and Hoxa9 NTD suggests that Meis-Pbx and Hox-Pbx (or Hox-Pbx-Meis) complexes co-occupy cellular promoters that drive leukemogenesis and that Meis1 CTD and Hox NTD cooperate in gene activation. Chromatin immunoprecipitation confirmed co-occupancy of Hoxa9 and Meis1 on the Flt3 promoter.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16648484      PMCID: PMC1488994          DOI: 10.1128/MCB.26.10.3902-3916.2006

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Sequential recruitment of HAT and SWI/SNF components to condensed chromatin by VP16.

Authors:  Sevinci Memedula; Andrew S Belmont
Journal:  Curr Biol       Date:  2003-02-04       Impact factor: 10.834

2.  LAB: a new membrane-associated adaptor molecule in B cell activation.

Authors:  Erin Janssen; Minghua Zhu; Weijia Zhang; Surapong Koonpaew; Weiguo Zhang
Journal:  Nat Immunol       Date:  2003-01-06       Impact factor: 25.606

3.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

4.  RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation.

Authors:  Shin-ichi Sakakibara; Yuki Nakamura; Tetsu Yoshida; Shinsuke Shibata; Masato Koike; Hiroshi Takano; Shuichi Ueda; Yasuo Uchiyama; Tetsuo Noda; Hideyuki Okano
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-29       Impact factor: 11.205

5.  Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites.

Authors:  Marieke Joosten; Yolanda Vankan-Berkhoudt; Marjolein Tas; Monja Lunghi; Yvonne Jenniskens; Evan Parganas; Peter J M Valk; Bob Löwenberg; Eric van den Akker; Ruud Delwel
Journal:  Oncogene       Date:  2002-10-17       Impact factor: 9.867

6.  Cell signaling switches HOX-PBX complexes from repressors to activators of transcription mediated by histone deacetylases and histone acetyltransferases.

Authors:  M Saleh; I Rambaldi; X J Yang; M S Featherstone
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

7.  Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia.

Authors:  U Thorsteinsdottir; E Kroon; L Jerome; F Blasi; G Sauvageau
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

8.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

9.  Frequent co-expression of HoxA9 and Meis1 genes in infant acute lymphoblastic leukaemia with MLL rearrangement.

Authors:  Toshihiko Imamura; Akira Morimoto; Mami Takanashi; Shigeyoshi Hibi; Tohru Sugimoto; Eiichi Ishii; Shinsaku Imashuku
Journal:  Br J Haematol       Date:  2002-10       Impact factor: 6.998

10.  Meis homeoproteins directly regulate Pax6 during vertebrate lens morphogenesis.

Authors:  Xin Zhang; Adam Friedman; Shaun Heaney; Patricia Purcell; Richard L Maas
Journal:  Genes Dev       Date:  2002-08-15       Impact factor: 11.361

View more
  44 in total

1.  Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Authors:  Yongsheng Huang; Kajal Sitwala; Joel Bronstein; Daniel Sanders; Monisha Dandekar; Cailin Collins; Gordon Robertson; James MacDonald; Timothee Cezard; Misha Bilenky; Nina Thiessen; Yongjun Zhao; Thomas Zeng; Martin Hirst; Alfred Hero; Steven Jones; Jay L Hess
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

2.  Down-regulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation.

Authors:  Kira Orlovsky; Alexander Kalinkovich; Tanya Rozovskaia; Elias Shezen; Tomer Itkin; Hansjuerg Alder; Hatice Gulcin Ozer; Letizia Carramusa; Abraham Avigdor; Stefano Volinia; Arthur Buchberg; Alex Mazo; Orit Kollet; Corey Largman; Carlo M Croce; Tatsuya Nakamura; Tsvee Lapidot; Eli Canaani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

3.  A cancer fate in the hands of a samurai.

Authors:  Malcolm A S Moore
Journal:  Nat Med       Date:  2010-09       Impact factor: 53.440

4.  Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression.

Authors:  James L Chen; Jianrong Li; Kyle J Kiriluk; Alex M Rosen; Gladell P Paner; Tatjana Antic; Yves A Lussier; Donald J Vander Griend
Journal:  Clin Cancer Res       Date:  2012-06-21       Impact factor: 12.531

Review 5.  Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Authors:  Michael G Kharas; Christopher J Lengner
Journal:  Trends Cancer       Date:  2017-04-08

6.  Hoxa9 regulates Flt3 in lymphohematopoietic progenitors.

Authors:  Kimberly Gwin; Elena Frank; Ayoko Bossou; Kay L Medina
Journal:  J Immunol       Date:  2010-10-22       Impact factor: 5.422

7.  Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia.

Authors:  Maria-Paz Garcia-Cuellar; Julia Steger; Elisa Füller; Katrin Hetzner; Robert K Slany
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

8.  HOX proteins and leukemia.

Authors:  Kajal V Sitwala; Monisha N Dandekar; Jay L Hess
Journal:  Int J Clin Exp Pathol       Date:  2008-03-30

Review 9.  Cancer gene discovery in mouse and man.

Authors:  Jenny Mattison; Louise van der Weyden; Tim Hubbard; David J Adams
Journal:  Biochim Biophys Acta       Date:  2009-03-12

10.  Transcriptional activation by MEIS1A in response to protein kinase A signaling requires the transducers of regulated CREB family of CREB co-activators.

Authors:  Siew-Lee Goh; Yvonne Looi; Hui Shen; Jun Fang; Caroline Bodner; Martin Houle; Andy Cheuk-Him Ng; Robert A Screaton; Mark Featherstone
Journal:  J Biol Chem       Date:  2009-05-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.